Neurosense Therapeutics Ltd (NRSN NASDAQ) stock market data APIs
$1.8984
-0.01(-0.5%)
as of July 3, 2025
Try our APIs with
free plan!
Neurosense Therapeutics Ltd Financial Data Overview
Price chart is built with
Anychart
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Prev. Close
1.8984
Open
1.8899
High
1.9051
Low
1.8216
52 wk Range
0.512-2.6
Market Cap
45 818 K
Shares Outstanding
23 989 K
EPS
-0.0775
Beta
1.599
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neurosense Therapeutics Ltd data using free add-ons & libraries
Get Neurosense Therapeutics Ltd Fundamental Data
Neurosense Therapeutics Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -9 880 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-08
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neurosense Therapeutics Ltd News
New
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
Last Wednesday, NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) said it scaled up its production of PrimeC to a commercial scale. PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release or...
NeuroSense Announces First Quarter 2024 Business Update
CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a...
Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now
MIAMI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 63rd Emerging Growth Conference on October 5th, 2023. ...
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 63rd Emerging Growth Conference on October 4th and 5th, 2023. ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
